African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials

Abstract

These results suggest that researchers will encounter challenges in recruiting African Americans to preclinical AD trials. Future research will be necessary to understand the optimal means to improve recruitment of underrepresented populations.